Navigation Links
NW Bio to Present at the Cancer Immunotherapy Summit

BETHESDA, Md., Feb. 29, 2012 /PRNewswire/ -- Northwest Biotherapeutics (OTC.BB: NWBO) (NW Bio) today announced that its COO, Anthony Maida III, Ph.D., MA, MBA, will be presenting at the Cancer Immunotherapy Conference as the lead afternoon speaker at 1:45 pm ET on Wednesday, February 29, 2012, in Boston, Massachusetts at the Metro Meeting Center at 101 Federal Street.


Dr. Maida's presentation, entitled "Developing Immune Therapies with Multiple Complementary Product Lines," will address the various components of developing a dendritic cell vaccine based on a patient's own tumor tissue. Using NW Bio's DCVax®-L vaccine platform technology for solid tumor cancers as an example, Dr. Maida will discuss the identification of clinically relevant tumor antigens (biomarkers), clinical trial design, assessment of immune response and clinical efficacy, and tumor evasion tactics.  In addition, Dr. Maida will address manufacturing with scale-up strategies, and commercial development of active immune therapies.

The three day conference on this rapidly expanding field of future cancer treatment potential is directed at featuring "industry innovators blazing a trail towards successful and sustained commercialization." Dr. Maida's longstanding experience in the field and NW Bio's progress to date will be presented in support of the Conference's key theme of "Re-engineering the Immune System for Effective Management of Cancer."  

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the US and Europe. 

The Company has a broad platform technology for dendritic cell-based vaccines.  The Company's lead clinical trial is a 240-patient Phase II trial in newly diagnosed Glioblastoma multiforme ("GBM"), the most aggressive and lethal brain cancer. In the earlier Phase I/II clinical trials for GBM brain cancer, patients who received DCVax® showed a median survival of 3 years compared with median survival of 14.6 months for patients who received standard of care (surgery, radiation and chemotherapy).  Patients who received DCVax® also experienced a substantially longer time to tumor recurrence: a median of 2 years, compared with 6.9 months in patients who received standard of care.  DCVax® was well-tolerated, with no toxic side effects.

The Company also previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in multiple other cancers.  The Company has also conducted a Phase I/II trial with DCVax® for recurrent metastatic ovarian cancer.  For further information about clinical sites and about the Company, please visit the Company's web site at


Statements made in this news release that are not historical facts, including statements concerning future treatment of patients with GBM using DCVax® and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements.  Actual results may differ materially from those projected in any forward-looking statement.  Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the timely performance of third parties, and whether the Company's products will demonstrate safety and efficacy.  Additional information on these and other factors, including Risk Factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings.  Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement.  You should not place undue reliance on any forward-looking statements.  The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws. 


SOURCE Northwest Biotherapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cempra, Inc. to Present at the Cowen and Company 32nd Annual Health Care Conference
2. Perrigo Company to Present at the RBC Capital Markets Healthcare Conference
3. Isis Pharmaceuticals to Present at the Cowen and Company 32nd Annual Health Care Conference
4. Frost & Sullivan New Product Innovation Award Presented to Brainsway for Its Deep Transcranial Magnetic Stimulation (dTMS) Device
5. Generex Subsidiary Antigen Express to Present at Prestigious Cancer Immunotherapy Summit
6. Masimo to Present at 24th Annual ROTH Conference
7. GP Strategies Corporation to Present at Baird Business Solutions Conference
8. Unigene to Present at IBCs 4th Annual AsiaTIDES Oligonucleotide and Peptide® Conference
9. Nektar Presents Positive Proof-of-Concept Clinical Data for Its New Opioid Molecule, NKTR-181, at American Academy of Pain Medicines 28th Annual Meeting
10. Optimer Pharmaceuticals to Present at the 32nd Annual Cowen Health Care Conference
11. Auxilium Pharmaceuticals to Present at the 2012 Cowen Healthcare Conference
Post Your Comments:
(Date:11/26/2015)... PUNE, India , November ... --> ... / personal emergency response system ... grow steadily for 5 years ... growing region expected to see ...
(Date:11/26/2015)... Bajos, November 26, 2015 Un ... de Bremachlorin para el cáncer avanzado.   ... la terapia fotodinámica de Bremachlorin para el cáncer avanzado. ... combina la inmunoterapia con la terapia fotodinámica de Bremachlorin ... Cancer Research . --> Clinical Cancer Research ...
(Date:11/26/2015)... 26 november 2015 AAIPharma Services ... geplande investering aan van ten minste $15,8 ... en het mondiale hoofdkantoor in ... resulteren in extra kantoorruimte en extra capaciteit ... groeiende behoeften van de farmaceutische en biotechnologische ...
Breaking Medicine Technology:
(Date:11/26/2015)... , ... November 26, 2015 , ... ... abuse located in central Michigan, have come together on Thanksgiving Day to share ... video, available for viewing on the Serenity Point YouTube channel, patients displayed what ...
(Date:11/26/2015)... ... November 26, 2015 , ... Inevitably when people think Thanksgiving, they ... to buy during the Black Friday and Cyber Monday massage chair sales ... the Internet high and low to find the best massage chair deals, they can ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... eReferral system for diagnostic imaging in the Waterloo region. Using the Ocean Platform, ... Medicine tests directly from their electronic medical record (EMR) without the need for ...
(Date:11/26/2015)... Ashburn, VA (PRWEB) , ... November 26, 2015 ... ... Planners, an American Express Travel Representative. As a franchise owner, Somu now offers ... range of cruise, destination wedding packages, private cruise sales, as well as, cabin ...
(Date:11/26/2015)... ... November 26, 2015 , ... The Catalent ... and the need to integrate dose form selection in early phase drug development. ... membership organization supporting and bringing together the UK’s emerging life sciences companies, corporate ...
Breaking Medicine News(10 mins):